The new Covid-19 mRNA vaccine developed by the United States based pharmaceutical company Moderna has the potential to offer humans administered with it protection from the disease for a time period that can extend to up to two years, said the company’s chief however according executive on Thursday.
However according to analysts and experts, for regulators to come to a definitive assessment of the period of efficacy provided by the vaccine, there is need for more data on its reaction on humans.
The European Commission granted emergency use approval for the Moderna’s vaccine on Wednesday. This relatively small US biotech company effectively surprised the industry and the world last year as it managed to develop a highly effective vaccine against the disease caused by the new coronavirus in just a few weeks.
However for scientists and regulators, the issue of how long the protection offered by a Covid-19 vaccine is a lingering question because of the fact that the development of vaccines and their pharmacovigilance usually requires years to assess accurately.
At an event organised by financial services group Oddo BHF, Moderna CEO Stephane Bancel said that dismissed the presumptions and the nightmare scenario that was being described in the media during the spring that the efficacy or the protecting power of a Covid-19 vaccine will only remain for a month or two and asked people to simply throw such presumptions “out of the window”.
Bancel further said that the process of the decay of the antibodies that are generated in a human body by the company’s vaccine against Cobid-19 is a very slow one and therefore the company believed that there will be protection for those people taking the vaccine shots for about “a couple of years”.
Moderna has also been working to examine the efficacy of its vaccine on the new variants of the coronavirus that have been discovered in the United Kingdom and South Africa and the company was about to prove that its vaccine would also be effective against those variants.
Those Covid-19 vaccines that have been developed recently should also be effective against both the newly found variants of the novel coronavirus, scientists have said.
(Adapted from LiveMint.com)